Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
RNA-seq (gene expression) · mouse · 15 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Topic
- CholangiocarcinomaThis series is part of our curated briefing on it.
- Samples
- 15 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Identification of PRMT5 as a therapeutic target in cholangiocarcinomaGut · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE270182_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1125385 and SRA study SRP514316. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 15 more — browse all 15 samples with per-sample file links →
- GSE317889 Combined DNA and RNA profiling refines prognostic stratification independent of therapeutic actionability in cholangiocarcinoma 62 samples same disease briefing · shares cholangiocarcinoma, therapeutic
- GSE274024 NOX4/NOX1 dual inhibition in cholangiocarcinoma as an effective approach to target TGF-beta protumorigenic actions in cancer associated fibroblasts 45 samples same disease briefing · shares cholangiocarcinoma, target
- GSE305958 CRISPR Screens Identify the ATPase VCP as a Druggable Therapeutic Vulnerability in Cholangiocarcinoma 14 samples same disease briefing · shares cholangiocarcinoma, therapeutic
- GSE295371 Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets 12 samples same disease briefing · shares therapeutic, target
- GSE273905 Targeting Cancer Associated Fibroblasts/Tumor Cells Cross-Talk Inhibits Intrahepatic Cholangiocarcinoma Progression 9 samples same disease briefing · shares cholangiocarcinoma, target
- GSE284669 Therapeutic Perturbation of Liver and Bile Duct Cancer through Targeted Inhibition of FSP1 and GCS Induced Ferroptosis 6 samples same disease briefing · shares therapeutic, target
- GSE262166 Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1 77 samples same disease briefing · shares cholangiocarcinoma, target
- GSE235891 Identification of RNF213 as a potential suppressor of local invasion in intrahepatic cholangiocarcinoma 18 samples same disease briefing · shares cholangiocarcinoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.